Industrializing immuno-oncology product manufacture and supply chain

CELL AND GENE THERAPY INSIGHTS

June 2022

Industrializing immuno-oncology product manufacture and supply chain

Download PDF

Expert Insight

A new era of in vivo gene therapy: the applicability of a differentiated HSV-1 based vector platform for redosable medicines

A new era of in vivo gene therapy: the applicability of a differentiated HSV-1 based vector platform for redosable medicines

Trevor Parry, Suma Krishnan, Domenick A Prosdocimo

Innovator Insight

Scaling non-viral cell therapy approaches for solid tumor treatments

Scaling non-viral cell therapy approaches for solid tumor treatments

Evan Zynda, Nektaria Andronikou, Kyle Jacoby

Commentary

Why we need a revolution for personalized cell therapies

Why we need a revolution for personalized cell therapies

S Steiner, B Gilgen, E Pernot et al.

Interview

Blazing a trail for commercial TCR T cell therapy

Blazing a trail for commercial TCR T cell therapy

Helen Tayton-Martin

Preparing next-gen cellular immunotherapies for commercialization

Preparing next-gen cellular immunotherapies for commercialization

FastFacts

Driving CAR-T from early-stage development to clinical filing and lot release

Driving CAR-T from early-stage development to clinical filing and lot release

Ulrike Herbrand, Julia Schueler, Sophie Vermond

Key considerations for cytokine supplier selection for cell therapies

Key considerations for cytokine supplier selection for cell therapies

Timothy Manning

Webinars

Thinking translational: Things to consider in CAR T cell research workflows

Thinking translational: Things to consider in CAR T cell research workflows

Saskia Rösch PhD

Forward engineering cell therapy production capabilities to save patient lives

Forward engineering cell therapy production capabilities to save patient lives

John Lee PhD